What is happening? Are the current acceptance criteria for therapeutic plasma adequate?

Lambrecht, 1991, Photoinactivation of viruses in human fresh plasma by phenothiazine dyes in combination with visible light, Vox Sang., 60, 207, 10.1111/j.1423-0410.1991.tb00907.x

Seghatchian, 2001, The quality of methylene blue light treated FFP and cryoprecipitate, Transfus. Apheresis. Sci., 25, 227, 10.1016/S1473-0502(01)00109-4

Williamson, 2003, Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety (review), Transfusion, 43, 322, 10.1046/j.1537-2995.2003.00483.x

Seghatchian, 2001, Current strategies for the prevision of safer plasma and its derivatives: an update, Transfu. Apheres. Sci., 25, 185, 10.1016/S1473-0502(01)00118-5

Pennington, 2002, Persistence of HTLV-1 in blood components after leukocyte depletion, Blood, 100, 677, 10.1182/blood.V100.2.677

Wagner, 2002, Virus inactivation in blood components by photoactive phenothiazine dyes, Transfus. Med. Rev., 16, 61, 10.1053/tmrv.2002.29405

Krailadsiri, 2001, Residual red cell and platelet contents in WBC-reduced plasma measured by a novel flowcytometric method, Transfus. Apheres. Sci., 24, 270, 10.1016/S1473-0502(01)00070-2

Seghatchian, 2003, Universal leucodepletion: an overview of some unreserved issues and the highlights of lessons learned, Transfus. Apheres. Sci., 29, 105, 10.1016/S1473-0502(03)00112-5

Burnouf, 2003, Residual cell content in plasma produced by three centrifugal apheresis procedures, Transfusion, 43, 1522, 10.1046/j.1537-2995.2003.00543.x

Solheim, 2003, Improved preservation of coagulation factors after prestorage leucocyte depletion of whole blood, Transfus. Apheres. Sci., 29, 133, 10.1016/S1473-0502(03)00117-4

Trindade, 2003, Filtration induces changes in activity states and leucocyte populations, Transfus. Apheres. Sci., 28, 319, 10.1016/S1473-0502(03)00052-1

De la Rubia, 2001, Role of methylene blue-treated or fresh plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura, Br. J. Haematol., 114, 721, 10.1046/j.1365-2141.2001.02991.x

Seghatchian, 1997, The quality of clinical FFP, cryoprecipitate, cryosupernatant-derived from single donor apheresis procedures and random donations collected in BAT system: assessment of the quality states of FVIII, contact activation, microvesicle content and cytokines, Transfus. Sci., 18, 115, 10.1016/S0955-3886(96)00086-0

Heiden, 2002, Quality of therapeutic plasma: requirements for marketing authorization, Thromb. Res., 107, 47, 10.1016/S0049-3848(02)00152-4

Sazama, 2003, Non-viral, non-hemolytic adverse effects of transfusion, Transfus. Apheresis. Sci., 29, 131, 10.1016/S1473-0502(03)00116-2

Simonson, 1999, Clinical tolerance of methylene blue virus-inactivated plasma, Vox Sang., 77, 210, 10.1046/j.1423-0410.1999.7740210.x

AuBuchon, 1998, Removal of methylene blue from plasma via an adsorbent filter, Vox Sang., 74, 1, 10.1046/j.1423-0410.1998.7410001.x

Wieding, 1999, Prospective, randomised and controlled study on solvent /detergent versus methylene blue light virus-inactivated plasma, Transfusion, 23

Aguzzi, 2004, Mammalian prion biology: one century of evolving concepts, Cell, 16, 313, 10.1016/S0092-8674(03)01031-6

Dzik, 2003, Apoptosis, TGF-beta and transfusion-related immunosuppression: biological versus clinical effects, Transfus. Apheres. Sci., 29, 127, 10.1016/S1473-0502(03)00115-0

Seghatchian, 2003, A novel method for the assessment of pro- and anti-coagulant properties of platelet-derived microvesicle and its usefulness for quality of platelet haemostatic function, Transfus. Apheres. Sci., 20, 119, 10.1016/S1473-0502(03)00113-7

Seghatchia, 2003, Blood cell apoptosis/necrosis: some laboratory and clinical aspects, Ann NO Y Sci, 1010, S40